Myriad Genetics
MYGN
258 hedge funds and large institutions have $2.75B invested in Myriad Genetics in 2018 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 76 increasing their positions, 95 reducing their positions, and 35 closing their positions.
35% more call options, than puts
Call options by funds: $8.79M | Put options by funds: $6.51M
23% more capital invested
Capital invested by funds: $2.22B → $2.75B (+$522M)
1% less funds holding
Funds holding: 260 → 258 (-2)
3% less first-time investments, than exits
New positions opened: 34 | Existing positions closed: 35
2.68% less ownership
Funds ownership: 107.76% → 105.08% (-2.7%)
20% less repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 95
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$23.3M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$17.4M |
| 3 |
MFIMFI
Mesirow Financial Investment Management - Fixed Income
Chicago,
Illinois
|
+$13.5M |
| 4 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
+$12.3M |
| 5 |
Millennium Management
New York
|
+$9.86M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$17.2M |
| 2 |
Goldman Sachs
New York
|
-$17.1M |
| 3 |
SI
Sensato Investors
San Francisco,
California
|
-$16.4M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$15.6M |
| 5 |
Russell Investments Group
London,
United Kingdom
|
-$15.1M |
MYGN Hedge Fund Activity: Q2 2018 in Review
258 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q2 2018, worth a combined $2.75B — up 23% from $2.22B a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of MYGN and 34 opened new positions — a net loss of 1 holder — while 95 trimmed existing stakes and 76 added.
The largest buyer was BlackRock, adding an estimated $23.3M. The largest seller was State Street, cutting an estimated $17.2M.
- 258 institutional investors held Myriad Genetics (MYGN) as of Q2 2018, down from 260 in Q1 2018.
- Funds reported $2.75B of Myriad Genetics stock for Q2 2018, up 23% quarter-over-quarter.
- 34 funds opened new Myriad Genetics positions in Q2 2018 and 35 closed out, a net change of -1 holder.
- The largest Myriad Genetics buyer in Q2 2018 was BlackRock, an estimated $23.3M added.
- The largest Myriad Genetics seller in Q2 2018 was State Street, an estimated $17.2M sold.
Based on aggregated 13F filings for Q2 2018.